PDS Biotechnology Corporation (PDSB)
| Market Cap | 106.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.34M |
| Shares Out | 28.45M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 374,333 |
| Open | 3.74 |
| Previous Close | 3.70 |
| Day's Range | 3.68 - 3.85 |
| 52-Week Range | 2.91 - 17.85 |
| Beta | 1.85 |
| Analysts | Buy |
| Price Target | 20.57 (+448.5%) |
| Earnings Date | Aug 11, 2022 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for PDSB stock is "Buy." The 12-month stock price forecast is 20.57, which is an increase of 448.53% from the latest price.
News
PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel
Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PDS Biotechnology's (NASDAQ: PDSB) lead drug candidate PDS0101 in combination with KEYTRUDA (pembrolizumab) for the trea...
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent...
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA ® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck c...
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refrac...
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months
PDS Biotech to Participate at Upcoming Investor Conferences
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer imm...
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results
Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annua...
FLORHAM PARK, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer i...
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., April 08, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer i...
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results
Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci...
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial ...
NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of the study NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refr...
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Mu...
Preliminary safety data has shown that PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer i...
PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated ...
The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer
PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium
FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Com...
Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes
PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
FLORHAM PARK, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...
PDS Biotech Announces Agreement with University of Georgia to License Novel Proteins for Versamune-based Universal Fl...
FLORHAM PARK, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Present at the 2021 International Head and Neck Cancer Conference
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccin...
PDS Biotech Pauses Recruitment In PDS0101 Combo Cancer Trial
PDS Biotechnology Corporation (NASDAQ: PDSB) has temporarily suspended recruitment in the National Cancer Institute (NCI)-led Phase 2 trial of PDS0101 combo trial in advanced HPV cancers The issue is no...
PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination
Temporary administrative suspension of recruitment – no safety or efficacy concerns related specifically to the novel PDS0101-based combination study Temporary administrative suspension of recruitment –...
PDS Biotechnology Announces Conference Call and Webcast to Present Third-Quarter 2021 Financial Results
FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Naïve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-1...
FLORHAM PARK, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propri...
PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's propr...
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination ...
No dose limiting toxicities observed in initial group of 12 patients No dose limiting toxicities observed in initial group of 12 patients